EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3 +/D120N mouse model of Lennox–Gastaut syndrome

Thomas Harman, Laura A Sharman, Ka Lai Yip, Miguel Bedoya-Pérez, Vaishali Janve, Jonathon C Arnold iD

Epilepsia Open · 2026-08 · 11 (4) · 1263-1275

DOI: 10.1002/epi4.70289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 11.06.2026. Verfasst von Thomas Harman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Anticonvulsants, Receptors, GABA-A, Cannabidiol. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lambert Initiative, Australian National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3 +/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and assessing their sensitivity to antiseizure agents.

Methods

Video‐EEG recordings of adult (10‐week‐old) KI and wild‐type (WT) littermates were scored for atypical absence seizures, and the acute effects of ethosuximide (200 mg/kg), ulixacaltamide (60 mg/kg), and cannabidiol (CBD, 100 mg/kg) on seizure incidence and duration were evaluated using a within‐subjects, crossover design. Video recordings of postnatal day 16 (P16) KI and WT littermates were scored for epileptic spasms, and the effects of once‐daily dosing with vigabatrin (100 mg/kg) and CBD (100 mg/kg) from P13 to P15 were evaluated against vehicle.

Results

Adult KI but not WT mice exhibited spontaneous atypical absence seizures. CBD, ethosuximide, and ulixacaltamide reduced seizure incidence and duration. Epileptic spasms were more frequent in KI than in WT mice at P16. CBD and vigabatrin significantly reduced spasm frequency compared to the vehicle. Significance Gabrb3 +/D120N mice display robust atypical absence seizures and neonatal spasms that respond to antiseizure agents, supporting the predictive validity of this model as a preclinical platform for LGS drug discovery. CBD produced reductions in both atypical absence seizures and infantile spasms, suggesting that this model may be utilized as a translational tool for evaluating novel cannabinoid therapeutics for DEEs. Plain Language Summary Lennox–Gastaut syndrome (LGS) is a rare type of epilepsy that's hard to treat and poses a challenge for developing new drugs. Finding suitable animal models that accurately represent LGS is crucial. This article describes the development of a mouse model of LGS with a genetic mutation that increases seizures and epileptic spasms. We tested how different antiseizure drugs affect the mice. CBD, ethosuximide, and ulixacaltamide reduced seizure incidence and duration. CBD and vigabatrin also reduced spasm frequency in young mice. These promising results suggest the mouse model could be a valuable tool for drug discovery in LGS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lennox Gastaut SyndromeAnticonvulsantsReceptors, GABA-ACannabidiolEpilepsy, AbsenceAnimalsMiceDisease Models, AnimalElectroencephalographyMaleFemaleSpasms, InfantileVigabatrin

Stichwörter der Autor:innen

GABRB3T‐type calcium channelsanimal modelsantiseizure drugscannabinoidsepileptic encephalopathy

Substanzen

AnticonvulsantsReceptors, GABA-ACannabidiolVigabatrin

Autor:innen und Institutionen

  • Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.
  • Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • School of Psychology, Faculty of Science, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Anesthesiology, Vanderbilt University, Nashville, Tennessee, USA.

ORCID-Profile: Jonathon C Arnold

Förderung

  • Lambert Initiative
  • Australian National Health and Medical Research Council

Zitieren

APA

Harman, T., Sharman, L. A., Yip, K. L., Bedoya-Pérez, M., Janve, V., & Arnold, J. C. (2026). Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3 +/D120N mouse model of Lennox–Gastaut syndrome. Epilepsia Open, 11(4), 1263-1275. https://doi.org/10.1002/epi4.70289

Vancouver

Harman T, Sharman LA, Yip KL, Bedoya-Pérez M, Janve V, Arnold JC. Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3 +/D120N mouse model of Lennox–Gastaut syndrome. Epilepsia Open. 2026;11(4):1263-1275. doi:10.1002/epi4.70289

BibTeX
@article{Harman2026,
  author = {Harman, Thomas and Sharman, Laura A and Yip, Ka Lai and Bedoya-Pérez, Miguel and Janve, Vaishali and Arnold, Jonathon C},
  title = {Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3 +/D120N mouse model of Lennox–Gastaut syndrome},
  journal = {Epilepsia Open},
  year = {2026},
  volume = {11},
  number = {4},
  pages = {1263--1275},
  doi = {10.1002/epi4.70289}
}
Kostenlos starten →